Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).
AOEs
CML
TKI
cardiovascular risk (CV risk)
cytokines
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
12
2021
accepted:
10
01
2022
entrez:
18
2
2022
pubmed:
19
2
2022
medline:
19
2
2022
Statut:
epublish
Résumé
Tyrosine kinase inhibitors (TKI) may offer a normal life expectancy to Chronic Myeloid Leukemia (CML) patients. However, a higher than expected incidence of arterial occlusive events (AOEs) was observed during treatment with nilotinib. We previously showed an "inflammatory status" during nilotinib that may explain the increased incidence of AOEs. Thus, we conducted this prospective KIARO study involving 186 CML patients (89 imatinib, 59 nilotinib, 38 dasatinib). Interleukin 6 (IL6), interleukin 10 (IL10), Tumor Necrosis Factor-α (TNFα), oxLDL, and high-sensitivity C-reactive protein (hs-CRP) plasma levels were measured at diagnosis and during treatment, with the aim to investigate changes in the inflammatory status favoring AOEs of each patient. Clinical and biochemical pro-atherothrombotic profiles and the 10-year SCORE chart were also evaluated. We showed a pro-inflammatory/pro-oxidative milieu increasing along treatment with nilotinib compared with imatinib or dasatinib, as demonstrated by higher hs-CRP and oxLDL levels and increased IL6/IL10 and TNFα/IL10 ratios only in nilotinib cohort. After median follow-up of 23.3 months starting from TKI, 10/186 patients (5.4%) suffered an AOE. Approximately 5/10 (50%) AOEs occurred during nilotinib treatment despite a lower 10-year SCORE and a lower median age in this subgroup. A longer follow-up is needed to further confirm the active role of nilotinib in AOEs pathogenesis.
Identifiants
pubmed: 35178353
doi: 10.3389/fonc.2022.835563
pmc: PMC8844441
doi:
Types de publication
Journal Article
Langues
eng
Pagination
835563Informations de copyright
Copyright © 2022 Sicuranza, Ferrigno, Abruzzese, Iurlo, Galimberti, Gozzini, Luciano, Stagno, Russo Rossi, Sgherza, Cattaneo, Zuanelli Brambilla, Marzano, Fava, Mulas, Cencini, Santoni, Sammartano, Gozzetti, Puccetti and Bocchia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51
pubmed: 22895665
Cardiovasc Res. 2006 Jan;69(1):36-45
pubmed: 16324688
Leukemia. 2013 Jun;27(6):1316-21
pubmed: 23459449
Ann Hematol. 2021 Aug;100(8):2005-2014
pubmed: 33388860
Leuk Lymphoma. 2019 Jan;60(1):189-199
pubmed: 29741440
Leukemia. 2021 Feb;35(2):440-453
pubmed: 33414482
Cardiovasc Res. 2005 Dec 1;68(3):353-4
pubmed: 16253212
Haematologica. 2015 Sep;100(9):1146-50
pubmed: 26113419
Blood Adv. 2019 Dec 23;3(24):4280-4290
pubmed: 31869412
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Ann Hematol. 2015 Mar;94(3):393-7
pubmed: 25304102
Oncotarget. 2016 Nov 1;7(44):72311-72321
pubmed: 27527867
Am J Hematol. 2018 Jul;93(7):E159-E161
pubmed: 29633312
Int J Behav Med. 2012 Dec;19(4):403-88
pubmed: 23093473
Clin Exp Med. 2006 Mar;6(1):38-44
pubmed: 16550343
Circulation. 2003 Feb 4;107(4):612-7
pubmed: 12566375
Hemasphere. 2020 Sep 30;4(5):e468
pubmed: 33134861
Hematol Oncol. 2019 Aug;37(3):296-302
pubmed: 30892724
Circulation. 2012 Dec 11;126(24):2890-909
pubmed: 23159553
J Biol Chem. 1997 Aug 22;272(34):20963-6
pubmed: 9261091
Arteriosclerosis. 1984 Jul-Aug;4(4):357-64
pubmed: 6466193
Haematologica. 2019 Aug;104(8):1589-1596
pubmed: 30819917
Eur J Prev Cardiol. 2015 Sep;22(2 Suppl):9-37
pubmed: 26195612
Leukemia. 2017 Nov;31(11):2388-2397
pubmed: 28757617
Cancers (Basel). 2020 Mar 30;12(4):
pubmed: 32235443
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Blood Adv. 2019 Mar 26;3(6):851-861
pubmed: 30885996
Curr Vasc Pharmacol. 2021;19(3):323-342
pubmed: 32188386
Leukemia. 2013 Jun;27(6):1310-5
pubmed: 23459450
Eur Cardiol. 2021 May 17;16:e20
pubmed: 34093741
Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1250-2
pubmed: 14557240